AmericanPeptide sells nothing. It reads what each vendor actually publishes and ranks them by one thing: the provenance tier of the purity claim. An independent, per-batch COA backs a third-party claim; a vendor’s own number backs a vendor-reported one. Same scale as the chemistry, the monographs, and everything else here — the Standard.
72 compounds with a ranked field of sources
GLP-1 / GIP / glucagon agonists and adipose-targeting peptides.
The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.
The once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
Dual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
Investigational once-weekly triple agonist (GIP / GLP-1 / glucagon) — the molecule some in the research community nickname "GLP-3" — with the largest weight reductions reported for any incretin-class agent.
Investigational glucagon / GLP-1 dual agonist from Boehringer Ingelheim — Phase 3 for obesity and MASH.
A glucagon / GLP-1 dual agonist (oxyntomodulin-based) approved in China for weight management and diabetes — not yet FDA-approved.
Long-acting amylin analog — Novo Nordisk’s answer to GLP-1 from a second satiety pathway, studied alone and as half of CagriSema. Phase 3 monotherapy reported ~11.8% mean weight loss.
Novo Nordisk’s fixed once-weekly combination of cagrilintide (amylin) + semaglutide (GLP-1) — 20.4%–22.7% mean weight loss in Phase 3, filed with the FDA in December 2025.
The lipolytic C-terminal fragment of human growth hormone — the parent peptide that AOD-9604 was engineered from.
C-terminal hGH fragment (177–191) historically investigated for lipolysis.
A fat-targeting proapoptotic peptide that destroys the blood supply of white fat — striking in animals, but discontinued in humans for kidney toxicity.
Small-molecule NNMT inhibitor (often catalogued alongside peptides).
GHRH analogs, GHRPs, and growth hormone secretagogues.
A splice variant of IGF-1 expressed after muscle damage; studied for satellite-cell activation.
Modified GHRH(1-29) analog with short plasma half-life.
Long-acting GHRH analog with a Drug Affinity Complex for albumin binding.
Selective ghrelin receptor agonist (GHRP) with minimal cortisol / prolactin release.
GHRH analog FDA-approved for HIV-associated lipodystrophy.
Truncated GHRH(1-29) — historically the first GHRH analog approved by the FDA.
Synthetic hexapeptide GHRP with potent GH-releasing activity.
Second-generation synthetic GHRP; a potent ghrelin-receptor agonist approved in Japan as a diagnostic for GH deficiency.
The original growth-hormone-releasing peptide — the tool compound that led scientists to the ghrelin receptor and, ultimately, to ghrelin itself.
An orally active, non-peptide ghrelin-receptor agonist and growth-hormone secretagogue — a small molecule catalogued alongside the GH peptides.
Tissue repair, angiogenesis, and regenerative peptides.
Synthetic gastric pentadecapeptide investigated for tendon, ligament, and GI repair.
Synthetic fragment of thymosin β4 studied for cell migration and tissue repair.
A 27-residue single-chain relaxin-2 analog and selective RXFP1 agonist — a simplified relaxin mimetic studied for anti-fibrotic effects.
An 11-amino-acid, non-erythropoietic fragment of erythropoietin that keeps EPO’s tissue-protective, anti-inflammatory activity without raising red blood cells.
Nootropics, neurotrophics, and synaptic modulators.
Synthetic Glu-Asp-Arg tripeptide studied as a brain/CNS bioregulator.
A natural brain / CNS peptide complex (Cytomax A-1) — the extract-based counterpart to Pinealon, targeting neuronal tissue.
Russian synthetic ACTH(4-10) analog studied for nootropic and neuroprotective effects.
Synthetic heptapeptide analog of tuftsin investigated as an anxiolytic.
Endogenous nonapeptide first isolated for its sleep-promoting properties.
A porcine-brain-derived mixture of neuropeptides and free amino acids with neurotrophic activity — approved for stroke and dementia outside the US.
An orally active angiotensin IV–derived peptidomimetic reported as an extraordinarily potent synaptogenic (synapse-forming) compound.
Senolytics, telomere, and aging-axis peptides.
Synthetic tetrapeptide investigated for telomerase activity and circadian effects.
The natural pineal peptide bioregulator — the animal-derived counterpart to synthetic Epitalon, marketed for aging and telomere support.
A senolytic D-retro-inverso peptide that selectively triggers apoptosis in senescent cells by disrupting the FOXO4–p53 interaction.
Pigmentation, hair, and skin-targeting peptides.
Endogenous copper-binding tripeptide widely studied in skin and hair biology.
Copper-binding tripeptide (Ala-His-Lys) studied for hair-follicle stimulation and dermal repair.
Palmitoylated matrikine peptide that signals fibroblasts to synthesize collagen — contains no copper.
A topical "neurocosmetic" hexapeptide that mimics SNAP-25 to soften expression wrinkles — often called topical Botox.
An elongated, higher-potency relative of Argireline — an eight-residue SNAP-25 mimic used as a topical, needle-free anti-wrinkle peptide.
Synthetic cyclic analog of α-MSH; non-selective melanocortin receptor agonist.
MC1R-selective α-MSH analog; FDA-approved (Scenesse) for photoprotection in erythropoietic protoporphyria.
HPG-axis, kisspeptin, and reproductive hormones.
Synthetic Lys-Glu-Asp-Gly tetrapeptide studied as a testis / reproductive-tissue bioregulator.
Synthetic Lys-Glu-Asp-Pro tetrapeptide studied as a prostate-tissue bioregulator — the defined-sequence successor to older prostate extracts.
A natural testis peptide complex (Cytomax A-12) — the extract-based counterpart to Testagen, targeting testicular tissue.
Melanocortin-4 receptor agonist FDA-approved for HSDD in premenopausal women.
C-terminal decapeptide fragment of kisspeptin; potent GnRH secretagogue.
Thymic peptides and immunomodulators.
Thymus-derived polypeptide complex — the founding tissue bioregulator (Cytomax) studied for immune restoration.
A synthetic thymic dipeptide (Glu-Trp) immunomodulator — the minimal active fragment distilled from thymus peptides.
Synthetic Lys-Glu dipeptide — the defined short-peptide successor to Thymalin, studied for immune and aging endpoints.
Synthetic Ala-Asp-Glu-Leu tetrapeptide studied as a respiratory-tissue bioregulator.
A natural thymus peptide complex (Cytomax A-6) — the extract-based counterpart to Thymalin, marketed for immune support and aging.
A natural bronchial peptide complex (Cytomax A-17) — the extract-based counterpart to Bronchogen, targeting respiratory tissue.
Thymus-derived 28-amino-acid peptide approved in many countries as an immunomodulator.
Human cathelicidin antimicrobial peptide active across bacteria, fungi, and viruses.
Anti-inflammatory C-terminal tripeptide of α-MSH.
Mitochondrial bioenergetics and NAD+ axis.
Mitochondrially-encoded peptide with reported insulin-sensitizing activity.
A 24-amino-acid mitochondrial-derived peptide with cytoprotective, anti-apoptotic activity — a companion to MOTS-c on the mitochondrial-signaling frontier.
Mitochondria-targeted cardiolipin-binding tetrapeptide.
Essential redox cofactor central to mitochondrial bioenergetics and sirtuin activity.
The body’s master antioxidant — a tripeptide (γ-Glu-Cys-Gly) sold as an injectable for antioxidant, detox, and skin-related use.
Short peptide bioregulators (Khavinson peptides) — tissue-specific gene-regulatory peptides.
Synthetic Lys-Glu-Asp tripeptide studied as a vascular-axis bioregulator.
Synthetic Ala-Glu-Asp-Arg tetrapeptide studied as a cardiac-tissue bioregulator.
Synthetic Lys-Glu-Asp-Trp tetrapeptide studied as a pancreas-tissue bioregulator.
A natural blood-vessel peptide complex (Cytomax A-3) — the extract-based counterpart to Vesugen, targeting vascular tissue.
A natural heart-muscle peptide complex (Cytomax A-14) — the extract-based counterpart to Cardiogen, targeting cardiac tissue.
A natural pancreas peptide complex (Cytomax A-7) — the extract-based counterpart to Pancragen, targeting pancreatic tissue.
A natural cartilage and bone peptide complex (Cytomax A-4) from the Khavinson bioregulator line, marketed for joint and connective-tissue support.
A natural skeletal-muscle peptide complex (Cytomax A-11) from the Khavinson bioregulator line, marketed for muscle-tissue support.
A natural liver peptide complex (Cytomax A-2) from the Khavinson bioregulator line, marketed for hepatic support.
A natural retina peptide complex (Cytomax A-5) from the Khavinson bioregulator line, marketed for eye and retinal support.